Aerie Pharmaceuticals Inc (NASDAQ:AERI) – Equities research analysts at Cantor Fitzgerald issued their FY2017 earnings per share estimates for shares of Aerie Pharmaceuticals in a report issued on Tuesday, Zacks Investment Research reports. Cantor Fitzgerald analyst E. Piros forecasts that the company will post earnings of ($3.23) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $56.00 price target on the stock.
Aerie Pharmaceuticals (NASDAQ:AERI) last announced its earnings results on Tuesday, March 7th. The company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.67) by $0.20.
AERI has been the topic of a number of other research reports. JMP Securities reiterated an “outperform” rating and set a $49.00 price objective on shares of Aerie Pharmaceuticals in a research note on Friday, December 23rd. Canaccord Genuity set a $50.00 price objective on Aerie Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, March 1st. Royal Bank of Canada reiterated an “outperform” rating and set a $55.00 price objective (up previously from $54.00) on shares of Aerie Pharmaceuticals in a research note on Wednesday, March 8th. Stifel Nicolaus upped their price objective on Aerie Pharmaceuticals from $55.00 to $65.00 and gave the stock a “buy” rating in a research note on Thursday, April 6th. Finally, Cowen and Company assumed coverage on Aerie Pharmaceuticals in a research note on Friday, February 24th. They set an “outperform” rating and a $70.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $57.62.
Aerie Pharmaceuticals (NASDAQ:AERI) traded down 2.37% during mid-day trading on Thursday, hitting $41.20. 299,949 shares of the company traded hands. The company’s market capitalization is $1.39 billion. The company’s 50-day moving average price is $45.75 and its 200 day moving average price is $41.37. Aerie Pharmaceuticals has a one year low of $12.56 and a one year high of $51.85.
A number of hedge funds and other institutional investors have recently bought and sold shares of AERI. Orbimed Advisors LLC boosted its position in Aerie Pharmaceuticals by 87.7% in the fourth quarter. Orbimed Advisors LLC now owns 1,496,000 shares of the company’s stock valued at $56,624,000 after buying an additional 698,900 shares during the last quarter. Deerfield Management Co. boosted its position in Aerie Pharmaceuticals by 37.3% in the fourth quarter. Deerfield Management Co. now owns 1,838,829 shares of the company’s stock valued at $69,600,000 after buying an additional 500,000 shares during the last quarter. Ameriprise Financial Inc. boosted its position in Aerie Pharmaceuticals by 279.8% in the third quarter. Ameriprise Financial Inc. now owns 595,292 shares of the company’s stock valued at $22,465,000 after buying an additional 438,563 shares during the last quarter. Baker BROS. Advisors LP purchased a new position in Aerie Pharmaceuticals during the third quarter valued at $11,298,000. Finally, State Street Corp boosted its position in Aerie Pharmaceuticals by 36.9% in the fourth quarter. State Street Corp now owns 820,644 shares of the company’s stock valued at $31,059,000 after buying an additional 221,146 shares during the last quarter. Hedge funds and other institutional investors own 95.69% of the company’s stock.
In other news, Director Gerald D. Cagle acquired 2,000 shares of the stock in a transaction on Wednesday, April 19th. The shares were purchased at an average price of $41.70 per share, for a total transaction of $83,400.00. Following the transaction, the director now directly owns 10,900 shares of the company’s stock, valued at $454,530. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Geoffrey M. Duyk sold 41,591 shares of the stock in a transaction on Wednesday, February 15th. The stock was sold at an average price of $46.63, for a total value of $1,939,388.33. Following the transaction, the director now owns 10,067 shares in the company, valued at approximately $469,424.21. The disclosure for this sale can be found here. 8.77% of the stock is currently owned by corporate insiders.
About Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aerie Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc and related companies with our FREE daily email newsletter.